JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $31

Benzinga · 11/17/2025 17:23
JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the price target from $33 to $31.